| Autor: |
Low, Jia Ming, Gu, Yue, Ng, Melissa Shu Feng, Amin, Zubair, Lee, Le Ye, Ng, Yvonne Peng Mei, Shunmuganathan, Bhuvaneshwari D/O, Niu, Yuxi, Gupta, Rashi, Tambyah, Paul Anantharajah, MacAry, Paul A., Wang, Liang Wei, Zhong, Youjia |
| Předmět: |
|
| Zdroj: |
NPJ Vaccines; 8/19/2021, Vol. 6 Issue 1, p1-8, 8p |
| Abstrakt: |
Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human milk as a result of COVID-19 vaccination is still unclear. In this study, we show that lactating mothers who received the BNT162b2 vaccine secreted SARS-CoV-2-specific IgA and IgG antibodies into milk, with the most significant increase at 3–7 days post-dose 2. Virus-specific IgG titers were stable out to 4–6 weeks after dose 2. In contrast, SARS-CoV-2-specific IgA levels showed substantial decay. Vaccine mRNA was detected in few milk samples (maximum of 2 ng/ml), indicative of minimal transfer. Additionally, infants who consumed post-vaccination human milk had no reported adverse effects up to 28 days post-ingestion. Our results define the safety and efficacy profiles of the vaccine in this demographic and provide initial evidence for protective immunity conferred by milk-borne SARS-CoV-2-specific antibodies. Taken together, our study supports recommendations for uninterrupted breastfeeding subsequent to mRNA vaccination against COVID-19. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
